Damora Therapeutics (DMRA)
Advances mutCALR-directed candidates for essential thrombocythemia and myelofibrosis.
$28.22
At close+0.08 (+0.28%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.52
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
———Mar '26May '26Aug '26Aug '26Nov '26
Reported———−$3.24−$0.62−$0.39−$0.39Pending
Estimate———−$0.14−$0.21−$0.40−$0.41−$0.52
Surprise———−2,216.4%−195.2%+2.9%+5.8%—
RevenueReportedEstimate
———Mar '26May '26Aug '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.52 | — | — |
| Aug 2026 | −$0.41 | −$0.39 | +5.8% |
| Aug 2026 | −$0.40 | −$0.39 | +2.9% |
| May 2026 | −$0.21 | −$0.62 | −195.2% |
| Mar 2026 | −$0.14 | −$3.24 | −2,216.4% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.52 | — | — | — | — | — | — |
| Aug 11, 2026 | −$0.41 | −$0.39 | +5.8% | — | — | — | +2.1% |
| Aug 10, 2026 | −$0.40 | −$0.39 | +2.9% | — | — | — | +2.8% |
| May 12, 2026 | −$0.21 | −$0.62 | −195.2% | — | — | — | +4.6% |
| Mar 18, 2026 | −$0.14 | −$3.24 | −2,216.4% | — | — | — | −9.2% |